The DOI matches its Crossref record.
Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib
Abstract
Purpose B-cell receptor signaling plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). However, blocking B-cell receptor signaling with dasatinib, an inhibitor of SRC kinase, produced variable results in preclinical and clinical studies. We aim to define the molecular mechanisms underlying the differential dasatinib sensitivity and to uncover more effective therapeutic targets in CLL. Experimental design Fresh CLL B cells were treated with dasatinib, and cell viability was followed. The CLL cases were then divided into good and poor responders. The cellular response was correlated with the activities of B-cell receptor signaling molecules, as well as with molecular and cytogenetic prognostic factors. Results Among 50 CLL cases, dasatinib treatment reduced cell viability by 2% to 90%, with an average reduction of 47% on day 4 of culture. The drug induced CLL cell death through the intrinsic apoptotic pathway mediated by reactive oxygen species. Unexpectedly, phosphorylation of SRC family kinases was inhibited by dasatinib in good, as well as poor, responders. As opposed to SRC family kinases, activities of two downstream molecules, SYK and phospholipase Cgamma2, correlate well with the apoptotic response of CLL cells to dasatinib. Conclusions Thus, SYK inhibition predicts cellular response to dasatinib. SYK, together with phospholipase Cgamma2, may serve as potential biomarkers to predict dasatinib therapeutic response in patients. From the pathog…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SYK/PLCγ2 activity is also suggested as a potential biomarker for responsiveness in the treatment of CLL and DLBCL, as their signaling activity correlated with cell death induced by treatment with the Src tyrosine kinase inhibitor, Dasatinib (133, 134).”
From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [134]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 41
- Dighiero, 2008, Chronic lymphocytic leukaemia, Lancet, 371, 1017, 10.1016/S0140-6736(08)60456-0 · DOI
- Damle, 1999, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, 94, 1840, 10.1182/blood.V94.6.1840 · DOI
- Hamblin, 1999, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia, Blood, 94, 1848, 10.1182/blood.V94.6.1848 · DOI
- Schroers, 2005, Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia, Leukemia, 19, 750, 10.1038/sj.leu.2403707 · DOI
- Orchard, 2004, ZAP-70 expression and prognosis in chronic lymphocytic leukaemia, Lancet, 363, 105, 10.1016/S0140-6736(03)15260-9 · DOI
- Schroeder, 1994, The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire, Immunol Today, 15, 288, 10.1016/0167-5699(94)90009-4 · DOI
- Rodriguez, 2007, Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation, Leukemia, 21, 1984, 10.1038/sj.leu.2404831 · DOI
- Dal Porto, 2004, B cell antigen receptor signaling 101, Mol Immunol, 41, 599, 10.1016/j.molimm.2004.04.008 · DOI
- Lanham, 2003, Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia, Blood, 101, 1087, 10.1182/blood-2002-06-1822 · DOI
- Nedellec, 2005, B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients, J Immunol, 174, 3749, 10.4049/jimmunol.174.6.3749 · DOI
- Deglesne, 2006, Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression, Cancer Res, 66, 7158, 10.1158/0008-5472.CAN-06-0085 · DOI
- Guarini, 2008, BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells, Blood, 112, 782, 10.1182/blood-2007-12-127688 · DOI
- Contri, 2005, Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis, J Clin Invest, 115, 369, 10.1172/JCI200522094 · DOI
- Veldurthy, 2008, The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes, Blood, 112, 1443, 10.1182/blood-2007-11-123984 · DOI
- Amrein, 2008, Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro, Br J Haematol, 143, 698, 10.1111/j.1365-2141.2008.07418.x · DOI
- Hallaert, 2008, c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches, Blood, 112, 5141, 10.1182/blood-2008-03-146704 · DOI
- Carter, 2005, Inhibition of drug-resistant mutants of ABL, KIT, EGF receptor kinases, Proc Natl Acad Sci U S A, 102, 11011, 10.1073/pnas.0504952102 · DOI
- Christopher, 2008, Metabolism and disposition of dasatinib after oral administration to humans, Drug Metab Dispos, 36, 1357, 10.1124/dmd.107.018267 · DOI · Paper page
- Amrein, 2008, Dasatinib has activity in relapsed/refractory chronic lymphocytic leukemia (CLL/SLL), a phase II trial, Blood (ASH Annual Meeting Abstract), 112, 3162
- Friedberg, 2008, Fostamatinib disodium (FosD), an oral inhibitor of Syk, is well-tolerated and has significant clinical activity in diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (SLL/CLL), Blood (ASH Annual Meeting Abstracts), 112, 3
- Jo, 2006, Peroxisome proliferator-activated receptor γ promotes lymphocyte survival through its actions on cellular metabolic activities, J Immunol, 177, 3737, 10.4049/jimmunol.177.6.3737 · DOI
- Yang, 2007, Activation of peroxisome proliferator-activated receptor γ contributes to the survival of T lymphoma cells by affecting cellular metabolism, Am J Pathol, 170, 722, 10.2353/ajpath.2007.060651 · DOI
- Wang, 2002, Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival, J Biol Chem, 277, 31781, 10.1074/jbc.M204279200 · DOI
- Gottlieb, 2000, Bcl-x(L) prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor α-induced apoptosis, Mol Cell Biol, 20, 5680, 10.1128/MCB.20.15.5680-5689.2000 · DOI
- Decaudin, 1997, Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents, Cancer Res, 57, 62
- Kroemer, 1998, The mitochondrial death/life regulator in apoptosis and necrosis, Annu Rev Physiol, 60, 619, 10.1146/annurev.physiol.60.1.619 · DOI
- Mignotte, 1998, Mitochondria and apoptosis, Eur J Biochem, 252, 1, 10.1046/j.1432-1327.1998.2520001.x · DOI
- Friesen, 1999, Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells, Cell Death Differ, 6, 471, 10.1038/sj.cdd.4400512 · DOI
- Green, 2004, The pathophysiology of mitochondrial cell death, Science, 305, 626, 10.1126/science.1099320 · DOI
- Hanada, 1993, bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia, Blood, 82, 1820, 10.1182/blood.V82.6.1820.1820 · DOI
- Otake, 2007, Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA, Blood, 109, 3069, 10.1182/blood-2006-08-043257 · DOI
- Wiestner, 2003, ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile, Blood, 101, 4944, 10.1182/blood-2002-10-3306 · DOI
- Durig, 2003, ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia, Leukemia, 17, 2426, 10.1038/sj.leu.2403147 · DOI
- Chen, 2005, ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia, Blood, 105, 2036, 10.1182/blood-2004-05-1715 · DOI
- Yang, 2008, Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib, Leukemia, 22, 1755, 10.1038/leu.2008.163 · DOI · Paper page
- Barragan, 2002, Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells, Blood, 99, 2969, 10.1182/blood.V99.8.2969 · DOI
- Ringshausen, 2002, Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cδ, Blood, 100, 3741, 10.1182/blood-2002-02-0539 · DOI
- Plate, 2004, PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation, Leuk Lymphoma, 45, 1519, 10.1080/10428190410001683642 · DOI
- Ticchioni, 2007, Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a, Oncogene, 26, 7081, 10.1038/sj.onc.1210519 · DOI
- Longo, 2008, The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells, Blood, 111, 846, 10.1182/blood-2007-05-089037 · DOI
- Chen, 2008, SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma, Blood, 111, 2230, 10.1182/blood-2007-07-100115 · DOI
Cited by
Sorted by citations
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298
Cheng, S., Ma, J., Guo, A., Lü, P., Leonard, J. P., Coleman, M., Liu, M., Buggy, J. J., Furman, R. R., & Wang, Y. L. (2013) · Leukemia · doi:10.1038/leu.2013.358 · Cited by 193
Self-citationCheng, S., Guo, A., Lu, P., Ma, J., Coleman, M., & Wang, Y. L. (2014) · Leukemia · doi:10.1038/leu.2014.263 · Cited by 162
Self-citationHematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells
Poh, A. R., O’Donoghue, R. J. J., & Ernst, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4199 · Cited by 147
“Dasatinib SFKs, BCR/ ABL, c-Kit, Ephrins, RTKs Reduced [174–177] Increased [178–180] Reduced [181, 182] Restored [123, 134] Prostate [183] and breast [184, 185] cancer”
BackgroundThe role of PLCγ2 in immunological disorders, cancer, and neurodegeneration
Jackson, J. T., Mulazzani, E., Nutt, S. L., & Masters, S. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100905 · Cited by 113
“SYK/PLCγ2 activity is also suggested as a potential biomarker for responsiveness in the treatment of CLL and DLBCL, as their signaling activity correlated with cell death induced by treatment with the Src tyrosine kinase inhibitor, Dasatinib (133, 134).”
BackgroundSYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng, S.-H., Coffey, G., Zhang, X., Shaknovich, R., Song, Z., Lu, P., Pandey, A., Melnick, A. M., Sinha, U., & Wang, Y. (2011) · Blood · doi:10.1182/blood-2011-02-333773 · Cited by 111
Self-citationCharacterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Ma, J., Lu, P., Guo, A., Cheng, S., Zong, H., Martin, P., Coleman, M., & Wang, Y. L. (2014) · British Journal of Haematology · doi:10.1111/bjh.12974 · Cited by 90
“…events better correlate with cellular responses of cells to the drug, we measured the phosphorylation levels of ERK and AKT in ibrutinib-treated MCL cells using phospho-flow assays that are sensitive and quantitative (Yang et al, 2008; Lu et al, 2009; Song et al, 2010; Cheng et al, 2011).”
BackgroundMethodInfluentialSelf-citationIdentification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
Sharma, S., Galanina, N., Guo, A., Lee, J., Kadri, S., Van Slambrouck, C., Long, B., Wang, W., Ming, M., Furtado, L. V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11932 · Cited by 90
Self-citationMcCaig, A. M., Cosimo, E., Leach, M. T. J., & Michie, A. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08507.x · Cited by 80
“Song et al (2010) concluded that Syk inhibitors may have more therapeutic potential than dasatinib in CLL.”
BackgroundResultMicroenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies
ten Hacken, E., & Burger, J. A. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.003 · Cited by 64
“In vitro, dasatinib has been demonstrated to inhibit BCR signaling and survival of CLL cells (Veldurthy et al., 2008; Song et al., 2010), also in the presence of microenvironmental stimuli including CD40L and IL4 (McCaig et al.”
BackgroundThe degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia
Roy, C. L., Deglesne, P., Chevallier, N., Beitar, T., Éclache, V., Quettier, M., Boubaya, M., Letestu, R., Lévy, V., Cymbalista, F., et al. (2012) · Blood · doi:10.1182/blood-2011-12-397158 · Cited by 62
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.
ten Hacken, E., Scielzo, C., Bertilaccio, M. T., Scarfò, L., Apollonio, B., Barbaglio, F., Stamatopoulos, K., Ponzoni, M., Ghia, P., & Caligaris-cappio, F. (2012) · Blood · doi:10.1182/blood-2012-09-457119 · Cited by 56
Marignac, V. L. M., Smith, S. E., Toban, N., Bazile, M., & Aloyz, R. S. (2013) · Oncotarget · doi:10.18632/oncotarget.1508 · Cited by 54
Zauli, G., Voltan, R., Bosco, R., Melloni, E., Marmiroli, S., Rigolin, G. M., Cuneo, A., & Secchiero, P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2572 · Cited by 49
“emanates via Syk and PLC-γ to the phosphatidylinositol (PI) 3-kinase/Akt axis (5, 26)”
p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
Amrein, L., Soulières, D., Johnston, J., & Aloyz, R. (2011) · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · doi:10.1016/j.leukres.2010.05.029 · Cited by 54
The Syk kinase as a therapeutic target in leukemia and lymphoma
Efremov, D. G., & Laurenti, L. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.570329 · Cited by 55
“Dasatinib Inhibitor of Src family kinases; does not inhibit Syk directly but blocks Syk activation by inhibiting the upstream Src kinases Induces apoptosis in primary CLL cells; apoptotic response depends on degree of Syk inhibition [65]”
BackgroundGuo, A., Lu, P., Galanina, N., Nabhan, C., Smith, S. M., Coleman, M., & Wang, Y. L. (2015) · Oncotarget · doi:10.18632/oncotarget.6727 · Cited by 51
“Veldurthy et al. [40] and our group [41] have both reported that dasatinib (primarily targeting LYN) generated a better in vitro apoptotic response in UM-CLL than M-CLL.”
Self-citationLu, P., Wang, S., Franzen, C. A., Venkataraman, G., McClure, R. F., Li, L., Wu, W., Niu, N., SUKHANOVA, M. J., Pei, J., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00429-z · Cited by 53
Self-citationHayden, R., Pratt, G., Roberts, C., Drayson, M., & Bunce, C. (2012) · Leukemia and Lymphoma · doi:10.3109/10428194.2011.610014 · Cited by 44
McCaig, A. M., Cosimo, E., Leach, M. T. J., & Michie, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048929 · Cited by 38
“Both our group and others have demonstrated that dasatinib inhibits BCR signal transduction and blocks BCR-mediated survival of CLL cells [9,10,11].”
BackgroundStepanek, O., Draber, P., Drobek, A., Horejsi, V., & Brdicka, T. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202401 · Cited by 31
E2A-PBX1 remodels oncogenic signaling networks in B-cell precursor acute lymphoid leukemia
Duque-Afonso, J., Lin, C.-H., Han, K., Wei, M., Feng, J., Kurzer, J. H., Schneidawind, C., Wong, S., Bassik, M., & Cleary, M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1899 · Cited by 28
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas
Uçkun, F., & Qazi, S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.112 · Cited by 27
Kater, A. P., Spiering, M., Liu, R. D., Raa, G. D. T., Slinger, E., Tonino, S. H., Beckers, M., Daenen, S. M. G. J., Doorduijn, J. K., Lankheet, N. A. G., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.10.004 · Cited by 27
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
Efremov, D. G., Wiestner, A. U., & Laurenti, L. (2012) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2012.067 · Cited by 20
“Targeting of LYN with SRC-family kinase inhibitors, such as PP2 and Dasatinib, induces leukemic cell apoptosis.(18,62,63) However, it is still uncertain whether the cytotoxic effect of these”
BackgroundAmrein, P. (2011) · Leukemia and Lymphoma · doi:10.3109/10428194.2011.555890 · Cited by 24
“Studies have shown that dasatinib induces apoptosis in freshly isolated CLL cells, particularly in those with unmutated IgVH genes, and inhibits SFK phosphorylation [41,42].”
BackgroundDebant, M., Hémon, P., Brigaudeau, C., Renaudineau, Y., & Mignen, O. (2015) · The International Journal of Developmental Biology · doi:10.1387/ijdb.150204om · Cited by 26
Guo, A., Lü, P., Lee, J. C., Zhen, C., Chiosis, G., & Wang, Y. L. (2017) · Oncogene · doi:10.1038/onc.2016.494 · Cited by 25
Self-citationKeizer, E., Wösten, H. A. B., & de Cock, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.534118 · Cited by 21
“Since dasatinib not only inhibits the activation of the EphA2 receptor but acts as a broad range tyrosine kinase inhibitor, also inhibiting BRC-Abl and Scr and Syk family kinases (Schade et al., 2008; Baell and Holloway, 2010; Song et al., 2010), we also used an EphA2-specific antibody.”
MethodInhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.
Wu, W., Wang, W., Franzen, C. A., Guo, H., Lee, J., Li, Y., Sukhanova, M., Sheng, D., Venkataraman, G., Mei, M., et al. (2018) · Blood Advances · doi:10.1182/blood-2018-99-118598 · Cited by 18
Self-citationSlupsky, J. R. (2014) · Scientifica · doi:10.1155/2014/208928 · Cited by 15
Mato, A. R., Jauhari, S., & Schuster, S. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24021 · Cited by 15
“As potential biomarkers of response, enhanced pretreatment SYK and phospholipase C gamma2 (PLCg2) activity levels predicted an apoptotic response to dasatinib in CLL cells [61].”
BackgroundSerpa, M., Bendit, I., Seguro, F., Xavier, F., Cavalcante, M., Steinbaum, D., Nardinelli, L., Aldred, V., de Paula, H. M., & Dorlhiac-Llacer, P. (2010) · Acta Haematologica · doi:10.1159/000318009 · Cited by 14
“Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in the Western World. It is characterized by the proliferation of mature CD5+ B cells, and its incidence is increased in men >65 years of age [ ,”
BackgroundPalomba, M., Piersanti, K., Ziegler, C. G. K., Decker, H., Cotari, J., Bantilan, K., Rijo, I., Gardner, J., Heaney, M., Bemis, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0079987 · Cited by 13
“reported how total SYK and PLCc2 phosphorylation upon dasatinib treatment (a SRC inhibitor) predicted the apoptotic response to the drug [45].”
BackgroundKuckertz, M., Patz, M., Veldurthy, A., Gehrke, I., Claasen, J., Frenzel, L., Wendtner, C., Hallek, M., & Krause, G. (2012) · Oncology Research and Treatment · doi:10.1159/000341081 · Cited by 13
Hutchinson, C., Natarajan, S. K., Johnson, S. M., Adams, J., Rees-Unwin, K., & Burthem, J. (2014) · Experimental Hematology & Oncology · doi:10.1186/2162-3619-3-7 · Cited by 8
Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia
Balakrishnan, K., & Gandhi, V. V. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668526 · Cited by 6
“As opposed to Src kinases, inhibition of SYK and PLCg2 quantitatively correlated with the degree of dasatinib-induced apoptotic response in CLL [37] implicating SYK as an important therapeutic target in B-CLL.”
BackgroundBourgne, C., Janel, A., Berger, J., Rapatel, C., Tournilhac, O., Hermet, É., Guerci, A., Lioret, F., Briançon, A., Bamdad, M., et al. (2015) · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · doi:10.1016/j.leukres.2014.11.014 · Cited by 6
In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia
Giannopoulos, K., Karczmarczyk, A., Karp, M., Bojarska-Junak, A., Kosior, K., Kowal, M., Tomczak, W., Hus, M., Machnicki, M. M., & Stokłosa, T. (2021) · Oncology Letters · doi:10.3892/ol.2021.12546 · Cited by 5
“The preclinical effi‐ cacy of dasatinib is due to inhibition of LYN and SFK kinases in CLL cells, overcoming pro‐survival signals from BCR and leading to apoptosis (8,20,31,32).”
BackgroundChen, X., Zhu, X., Wei, Z., & Lv, Q. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29294 · Cited by 5
“Also, Song et al10 observed a strong correlation between PLCγ2 activity suppression and the maximal rate of chronic lymphocytic leukemia cell death, thus validating the tumor‐promoting function of PLCγ2 in this type of leukemia.”
BackgroundProteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia
Alsagaby, S., Brewis, I., Vijayakumar, R., Alhumaydhi, F., Alwashmi, A. S., Alharbi, N., Abdulmonem, W. A., Premanathan, M., Pratt, G., Fegan, C., et al. (2021) · Electronic Journal of Biotechnology · doi:10.1016/j.ejbt.2021.04.006 · Cited by 2
Lu, P., Franzen, C. A., Vistarop, A., Efimov, A., Shahriyar, S. A., Wang, S., Rao, S., Messmer, M., Nakhoda, S., Cukierman, E., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100142 · Cited by 1
“19,20 Recognizing this deficiency, we have developed a novel and simple ex vivo model that incorporates the tumor microenvironment (TME).”
Self-citationBioinformatic mining of kinase inhibitors that regulate autophagy through kinase signaling pathways.
Yang, Y., Ma, B., Jin, Y., Ben, W., Zhang, D., Jiang, K., Feng, S.-J., Huang, L., & Zheng, J.-H. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2663 · Cited by 1
Quettier, M. (2015) · theses.fr (ABES) · doi:10.70675/3dc44105z2574z4790zb6abz85a45bdf97bf
“En effet, le pourcentage de diminution de la phosphorylation de PLCγ2 dans les cellules traitées avec le Dasatinib est corrélé à la mortalité cellulaire [259].”
BackgroundSignal Transduction Therapies for Treatment of Chronic Leukemias
Kaymaz, B. (2014) · Global Journal of Hematology and Blood Transfusion · doi:10.15379/2408-9877.2014.01.01.5
“Targeting LYN with SRC-family kinase inhibitors such as PP2 and Dasatinib resulted in induced leukemic cell apoptosis [29-30].”
BackgroundPalomba, M., Piersanti, K., Ziegler, C. G. K., Cotari, J., Balderas, R., Malek, S. N., Seymour, E. K., Zelenetz, A., van den Brink, M. R., & Altan-Bonnet, G. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-2886
“reported how total SYK and PLCc2 phosphorylation upon dasatinib treatment (a SRC inhibitor) predicted the apoptotic response to the drug [45].”
BackgroundMethods for SNP Regression Analysis in Clinical Studies
LeBlanc, M., Goldman, B., & Kooperberg, C. (2012) · doi:10.1201/b11800-37
“Investigations of the association of patient outcome with a few candidate single nucleotide polymorphisms (SNPs) or much larger numbers of SNPs have been undertaken in various therapeutic studies in oncology (e.g., Durie et al. 2009, Song et al. 2010).”
BackgroundIn Vitro Sensitivity Testing in the Assessment of Anti-CLL Drug Candidates
Krause, G., Kuckertz, M., Kerwien, S., Patz, M., & Hallek, M. (2012) · InTech eBooks · doi:10.5772/27087
“The extent of dasatinib-induced apoptosis in CLL cells corresponds to the concomitant decrease in the phosphorylation of the direct SFK substrates Syk and phospholipase C-γ (Song et al., 2010).”
Background
Metadata
- Authors
- Song, Z., Lu, P., Furman, R. R., Leonard, J. P., Martin, P., Tyrell, L., Lee, F. Y., Knowles, D. M., Coleman, M., & Wang, Y. L.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2010-01-14
- Volume
- 16
- Issue
- 2
- Pages
- 587-599
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2042132765
- Cited by
- 59
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2021: 7 · 2020: 1 · 2019: 1 · 2017: 1 · 2016: 2 · 2015: 5 · 2014: 13 · 2013: 6 · 2012: 9
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Weill Cornell Medical College
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- chronic lymphocytic leukemia, dasatinib, Syk, PLCγ2, Src family kinases, B cell receptor signaling, apoptosis, reactive oxygen species, predictive biomarkers, therapeutic target
- MeSH terms
- Dasatinib, Syk Kinase, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Enzyme Activation, Female, Humans, Male, Middle Aged, Prognosis, Protein-Tyrosine Kinases, Pyrimidines, Thiazoles, Tumor Cells, Cultured, Leukemia, Lymphocytic, Chronic, B-Cell, Cell Death, Apoptosis, src-Family Kinases, Protein Kinase Inhibitors, Intracellular Signaling Peptides and Proteins, Phospholipase C gamma, Biomarkers, Pharmacological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
